 |
3 Diseases |  |
5 Trials |
|
5 Trials |  |
20 News |  |
| 12» |
- utidelone IV (UTD1) / Beijing Biostar Technologies
A genetically engineered epothilone analog as a novel oral microtubule inhibitor: A clinical study of utidelone capsule for advanced breast cancer. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6782;
P1
This study is still actively enrolling; further data will be provided at the time of presentation. Clinical trial information: NCT05700084.
- utidelone IV (UTD1) / Beijing Biostar Technologies
Utidelone for heavily pretreated metastatic castration-resistant prostate cancer after failing docetaxel treatment: An open-label, single-arm, phase II trial. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6732;
Additional randomized trials are warranted for this new regimen. Clinical trial information: ChiCTR2200061635.
- Tyvyt (sintilimab) / Eli Lilly, utidelone IV (UTD1) / Beijing Biostar Technologies
A single-arm, multicenter, phase II study of utidelone in advanced solid tumors: Efficacy data from screening and the expansion cohort assessing utidelone plus sintilimab and oxaliplatin for advanced gastric cancer. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5237;
P2
Utidelone plus sintilimab and oxaliplatin demonstrated promising efficacy and an acceptable safety profile as first-line treatment for pts with GC. Stage II of the USO-G study is still actively enrolling; further data will be provided at the time of presentation.
- utidelone IV (UTD1) / Beijing Biostar Technologies
A novel oral microtubule inhibitor utidelone capsule (UTD2): A phase 1 clinical study to assess the tolerability, safety, and efficacy in advanced solid tumors. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4662;
P1
This study is still actively ongoing, and further data will be provided at time of presentation. Clinical trial information: NCT05681000.
- Avastin (bevacizumab) / Roche, utidelone IV (UTD1) / Beijing Biostar Technologies
Utidelone plus bevacizumab for the treatment of HER2-negative breast cancer brain metastases (U-BOMB): A multicenter, single-arm phase II study. (Hall A; Poster Bd #: 59) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2511;
P2
Clinical trial information: NCT05681000. This study preliminarily shows promising efficacy and manageable safety of the combination of utidelone and bevacizumab in the treatment of HER2-negative metastatic breast cancer patients with brain metastases.
- || utidelone IV (UTD1) / Beijing Biostar Technologies
P2 data, Journal, Metastases: Efficacy and safety of utidelone for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer who have failed standard second-line treatment: A phase 2 clinical trial (BG01-1801). (Pubmed Central) - Apr 11, 2024
P2
Further clinical studies are warranted to confirm its role in NSCLC treatment. No.NCT03693547; https://classic.clinicaltrials.gov.
- | Enrollment open, Metastases: ORIENTA: Organoid-based Functional Precision Therapy for Advanced Breast Cancer (clinicaltrials.gov) - Dec 29, 2023
P2, N=252, Recruiting, Sponsor: Guangdong Provincial People's Hospital
No.NCT03693547; https://classic.clinicaltrials.gov. Not yet recruiting --> Recruiting
- || utidelone IV (UTD1) / Beijing Biostar Technologies
Review, Journal, Metastases: A new strategy for the treatment of heavily pretreated metastatic breast cancer: A case report and review of the literature. (Pubmed Central) - Dec 5, 2023
To our knowledge, this is the first report of utidelone plus capecitabine successfully treating a patient with heavily pretreated metastatic breast cancer. This combined treatment offers a new option for patients with multi-drug resistant breast cancer.
- | Tevimbra (tislelizumab) / BeiGene, Avastin (bevacizumab) / Roche, utidelone IV (UTD1) / Beijing Biostar Technologies
New P2 trial, Metastases: The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ?Single-arm, Prospective, Open Clinical Study (clinicaltrials.gov) - Nov 8, 2023
P2, N=78, Recruiting, Sponsor: Huihua Xiong
- || utidelone IV (UTD1) / Beijing Biostar Technologies
Trial completion date, Trial primary completion date, Monotherapy, Metastases: Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Nov 8, 2023
P2, N=120, Recruiting, Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd.
This combined treatment offers a new option for patients with multi-drug resistant breast cancer. Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Aug 2023 --> Mar 2024
- |||||| utidelone IV (UTD1) / Beijing Biostar Technologies
Enrollment open, Trial initiation date, Metastases: Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - Nov 8, 2023
P3, N=612, Recruiting, Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd.
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Aug 2023 --> Mar 2024 Not yet recruiting --> Recruiting | Initiation date: Jan 2023 --> May 2023
- |||||| utidelone IV (UTD1) / Beijing Biostar Technologies
Enrollment open, Trial initiation date, Combination therapy, Metastases: Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer (clinicaltrials.gov) - Nov 8, 2023
P3, N=552, Recruiting, Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd.
Not yet recruiting --> Recruiting | Initiation date: Jan 2023 --> May 2023 Not yet recruiting --> Recruiting | Initiation date: Jan 2023 --> May 2023
- | New P2 trial, Metastases: ORIENTA: Organoid-based Functional Precision Therapy for Advanced Breast Cancer (clinicaltrials.gov) - Oct 25, 2023
P2, N=252, Not yet recruiting, Sponsor: Guangdong Provincial People's Hospital
- utidelone IV (UTD1) / Beijing Biostar Technologies
Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial (Exhibition area) - Oct 6, 2023 - Abstract #ESMOAsia2023ESMO_Asia_648;
Conclusions This study demonstrated a promising anti-tumor activity of utidelone in patients with metastatic solid tumors after failure of the standard therapies, especially in patients with breast cand gynecological cancers. Moreover, 120h continuous intravenous infusion is a more tolerable administration method than 5 days intermittent infusion, worthy further study.
- | Cipterbin (inetetamab) / 3SBio, utidelone IV (UTD1) / Beijing Biostar Technologies
Enrollment closed, Trial completion date, Metastases: Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone. (clinicaltrials.gov) - Sep 25, 2023
P2, N=46, Active, not recruiting, Sponsor: Henan Cancer Hospital
Moreover, 120h continuous intravenous infusion is a more tolerable administration method than 5 days intermittent infusion, worthy further study. Recruiting --> Active, not recruiting | Trial completion date: Oct 2022 --> Dec 2024
- | utidelone IV (UTD1) / Beijing Biostar Technologies
New P2 trial, Metastases: Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer (clinicaltrials.gov) - Aug 9, 2023
P2, N=181, Not yet recruiting, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- utidelone IV (UTD1) / Beijing Biostar Technologies
Efficacy and safety of utidelone in previously treated patients with advanced or metastatic soft tissue sarcomas (HX-SARC02): A prospective, single-arm, phase II study () - Jul 27, 2023 - Abstract #ESMO2023ESMO_3397;
No treatment-related deaths occurred. Conclusions The present study demonstrated a promising anti-tumour activity of utidelone in patients with advanced or metastatic STSs who were previously treated with and refractory to both anthracycline-based chemotherapy and large-spectrum tyrosine kinase inhibitor.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio, utidelone IV (UTD1) / Beijing Biostar Technologies
Preliminary results from a prospective study of inetetamab in combination with pyrotinib and utidelone for HER2-positive metastatic breast cancer (IPUtrial) () - Jul 27, 2023 - Abstract #ESMO2023ESMO_2043;
Conclusions Inetetamab plus pyrotinib and utidelone may be an excellent scheme for HER2-positive metastatic breast cancer. This trial is still ongoing and needs long-term follow-up.
- Avastin (bevacizumab) / Roche, utidelone IV (UTD1) / Beijing Biostar Technologies
Utidelone in combination with etoposide and bevacizumab in HER2-negative breast cancer with brain metastasis (UTOBIA-BM): A prospective, single-arm, phase II trial () - Jul 27, 2023 - Abstract #ESMO2023ESMO_2009;
P=N/A
No treatment-related death occurred. Conclusions Utidelone in combination with etoposide and bevacizumab has shown anti-tumor activity and manageable toxicity in breast cancer pts with brain metastasis, and a randomized control trial is warrantied.
- | utidelone IV (UTD1) / Beijing Biostar Technologies
New P2 trial, Metastases: Utidelone Treated for the Recurrent or Metastatic Urothelial Carcinoma (clinicaltrials.gov) - Jun 9, 2023
P2, N=34, Recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- || Focus V (anlotinib) / Advenchen, Sino Biopharm, utidelone IV (UTD1) / Beijing Biostar Technologies
New P2 trial, Metastases: Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer (clinicaltrials.gov) - May 19, 2023
P2, N=47, Recruiting, Sponsor: Peking University
- Cipterbin (inetetamab) / 3SBio, AiRuiKa (camrelizumab) / Jiangsu Hengrui Pharma, utidelone (UTD1) / Beijing Biostar Technologies
Anti-HER2 antibody inetetamab plus camrelizumab and utidelone for pretreated HER2-positive metastatic breast cancer: Final results from the phase 2 ICU trial. (On Demand | Hall A; Poster Bd # 263) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3234;
P2
The ICU study showed a favorable benefit-risk profile and is an important option for Chinese patients with HER2-positive MBC after at least two lines of HER2-directed therapies with trastuzumab and TKIs. Clinical trial information: NCT04681287.
- || Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap, epothilone D (BMS-241027) / BMS, utidelone (UTD1) / Beijing Biostar Technologies
Review, Journal: Epothilones as Natural Compounds for Novel Anticancer Drugs Development. (Pubmed Central) - Apr 13, 2023
In recent years innovative synthetic strategies resulted in the synthesis of new epothilone derivatives with improved activity against refractory tumors with better activities when compared to ixabepilone or taxol. These compounds together with specific delivery mechanisms could be developed in anti-cancer drugs.
- | utidelone IV (UTD1) / Beijing Biostar Technologies
New P2 trial, Metastases: Utidelone Injection Combined With Gemcitabine in First-line Chemotherapy for Unresectable Advanced Pancreatic Cancer (clinicaltrials.gov) - Apr 3, 2023
P2, N=92, Recruiting, Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- |||||| utidelone IV (UTD1) / Beijing Biostar Technologies
Enrollment open, Metastases: Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Jan 31, 2023
P3, N=349, Recruiting, Sponsor: Sun Yat-sen University
These compounds together with specific delivery mechanisms could be developed in anti-cancer drugs. Not yet recruiting --> Recruiting
- || utidelone oral (UTD2) / Beijing Biostar Technologies, utidelone IV (UTD1) / Beijing Biostar Technologies
New P1 trial, Metastases: Tolerability and Bioavailability of Utidelone Capsule in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jan 26, 2023
P1, N=38, Not yet recruiting, Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd.
- | utidelone oral (UTD2) / Beijing Biostar Technologies, utidelone IV (UTD1) / Beijing Biostar Technologies
New P1 trial, Metastases: Tolerability of Utidelone Capsule in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jan 11, 2023
P1, N=28, Not yet recruiting, Sponsor: Biostar Pharma, Inc.
- || utidelone IV (UTD1) / Beijing Biostar Technologies
Trial completion date, Trial primary completion date, Monotherapy, Metastases: Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jan 10, 2023
P2, N=120, Recruiting, Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd.
Not yet recruiting --> Recruiting Trial completion date: Jun 2022 --> Dec 2023 | Trial primary completion date: Jun 2022 --> Aug 2023
- ||| utidelone IV (UTD1) / Beijing Biostar Technologies
Trial completion date, Trial suspension, Trial primary completion date, Monotherapy, Metastases: Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 10, 2023
P2, N=30, Suspended, Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd.
Trial completion date: Jun 2022 --> Dec 2023 | Trial primary completion date: Jun 2022 --> Aug 2023 Trial completion date: Dec 2022 --> Dec 2024 | Recruiting --> Suspended | Trial primary completion date: Apr 2022 --> Dec 2023
- || utidelone IV (UTD1) / Beijing Biostar Technologies
Trial completion, Metastases: PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast Cancer (clinicaltrials.gov) - Jan 10, 2023
P1, N=16, Completed, Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd.
Trial completion date: Dec 2022 --> Dec 2024 | Recruiting --> Suspended | Trial primary completion date: Apr 2022 --> Dec 2023 Recruiting --> Completed
- || utidelone IV (UTD1) / Beijing Biostar Technologies
Trial completion, Monotherapy, Metastases: Clinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer?NSCLC? (clinicaltrials.gov) - Jan 10, 2023
P2, N=26, Completed, Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd.
Recruiting --> Completed Recruiting --> Completed
- |||||||||| utidelone IV (UTD1) / Beijing Biostar Technologies
New P3 trial, Metastases: Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jan 6, 2023
P3, N=612, Not yet recruiting, Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd.
- |||||||||| utidelone IV (UTD1) / Beijing Biostar Technologies
New P3 trial, Combination therapy, Metastases: Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer (clinicaltrials.gov) - Jan 6, 2023
P3, N=552, Not yet recruiting, Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd.
- | Avastin (bevacizumab) / Roche, utidelone IV (UTD1) / Beijing Biostar Technologies
Enrollment open, Metastases: Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases (clinicaltrials.gov) - Sep 16, 2022
P2, N=100, Recruiting, Sponsor: Henan Cancer Hospital
Recruiting --> Completed Not yet recruiting --> Recruiting
- | Cipterbin (inetetamab) / 3SBio, utidelone IV (UTD1) / Beijing Biostar Technologies
Trial primary completion date, Metastases: Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone. (clinicaltrials.gov) - Aug 3, 2022
P2, N=46, Recruiting, Sponsor: Henan Cancer Hospital
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2022 --> Nov 2021
- |||||||||| utidelone IV (UTD1) / Beijing Biostar Technologies
New P3 trial, Metastases: Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Jun 23, 2022
P3, N=349, Not yet recruiting, Sponsor: Sun Yat-sen University
- | utidelone IV (UTD1) / Beijing Biostar Technologies
New P2 trial, Metastases: Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Jun 2, 2022
P2, N=61, Not yet recruiting, Sponsor: Fudan University
- |||| Avastin (bevacizumab) / Roche, utidelone IV (UTD1) / Beijing Biostar Technologies
New P2 trial, Metastases: Utidelone Combined With Bevacizumab in the Treatment of ? 2 Lines of HER-2 Negative Advanced Breast Cancer (clinicaltrials.gov) - May 31, 2022
P2, N=71, Not yet recruiting, Sponsor: Henan Cancer Hospital
- | Avastin (bevacizumab) / Roche, utidelone IV (UTD1) / Beijing Biostar Technologies
New P2 trial, Metastases: Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases (clinicaltrials.gov) - May 1, 2022
P2, N=100, Not yet recruiting, Sponsor: Henan Cancer Hospital
- Cipterbin (inetetamab) / 3SBio, AiRuiKa (camrelizumab) / Jiangsu Hengrui Pharma, utidelone (UTD1) / Beijing Biostar Technologies
Anti-HER2 antibody inetetamab plus camrelizumab and utidelone for pretreated HER2-positive advanced breast cancer: A single-arm, multicenter, phase 2 study. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_1272;
P2
Previous HER2-targeted therapies included trastuzumab (20 [100%]), pyrotinib (17 [85%]), lapatinib (7 [35%]), pertuzumab (3 [15%]), and margetuximab (2 [10%]). Inetetamab plus camrelizumab and utidelone showed promising efficacy and acceptable safety profile in patients with HER2-positive advanced breast cancer after progression on at least two lines of HER2-directed therapies with trastuzumab and TKIs.
- | utidelone IV (UTD1) / Beijing Biostar Technologies
New P2 trial: Utidelone in Third-line and Above Treatment of Small Cell Lung Cancer (clinicaltrials.gov) - Mar 27, 2022
P2, N=40, Recruiting, Sponsor: Henan Cancer Hospital
- utidelone (UTD1) / Beijing Biostar Technologies
Efficacy and safety of utidelone in treatment-refractory advanced non-small cell lung cancer ([VIRTUAL]) - Feb 19, 2022 - Abstract #ELCC2022ELCC_304;
P2
Notably, low incidences of liver and renal toxicities, and very limited gastrointestinal toxic effect were observed. Conclusions These findings demonstrate that utidelone may be an effective treatment option for advanced NSCLC refractory to second-line treatment.
- | utidelone IV (UTD1) / Beijing Biostar Technologies
New P3 trial, Metastases: Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Dec 28, 2021
P3, N=512, Not yet recruiting, Sponsor: Sun Yat-sen University
- | Halaven (eribulin mesylate) / Eisai
Retrospective data, Journal: Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer. (Pubmed Central) - Nov 4, 2021
This network meta-analysis suggests that ERI may provide an overall survival benefit in the overall locally advanced breast cancer/metastatic breast cancer populations and triple negative breast cancer subgroup compared to standard treatments. These findings support the use of ERI in second- or later-line treatment of patients with locally advanced breast cancer/metastatic breast cancer.
- || utidelone IV (UTD1) / Beijing Biostar Technologies
New P1 trial, Metastases: PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast Cancer (clinicaltrials.gov) - Sep 21, 2021
P1, N=16, Recruiting, Sponsor: Beijing Biostar Technologies, Ltd
- | utidelone (UTD1) / Beijing Biostar Technologies
Journal, PARP Biomarker: Utidelone inhibits growth of colorectal cancer cells through ROS/JNK signaling pathway. (Pubmed Central) - Sep 19, 2021
Utidelone (UTD1), a novel microtubule stabilizing agent, is an epothilone B analogue which was produced by genetic engineering...Moreover, UTD1 inhibited tumor growth and was more effective and safer compared with paclitaxel and 5-FU in RKO xenograft in nude mice. Taken together, our findings first indicate that UDT1 inhibits tumor growth in CRC xenograft model and may be a promising agent for CRC treatment.
- | utidelone IV (UTD1) / Beijing Biostar Technologies
Trial completion date, Trial primary completion date, Monotherapy, Metastases: Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 30, 2021
P2, N=30, Recruiting, Sponsor: Beijing Biostar Technologies, Ltd
Taken together, our findings first indicate that UDT1 inhibits tumor growth in CRC xenograft model and may be a promising agent for CRC treatment. Trial completion date: Jun 2021 --> Dec 2022 | Trial primary completion date: Apr 2021 --> Apr 2022
- | Cipterbin (inetetamab) / 3SBio, utidelone IV (UTD1) / Beijing Biostar Technologies
Enrollment open, Metastases: Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone. (clinicaltrials.gov) - Aug 25, 2021
P2, N=46, Recruiting, Sponsor: Henan Cancer Hospital
Trial completion date: Jun 2021 --> Dec 2022 | Trial primary completion date: Apr 2021 --> Apr 2022 Not yet recruiting --> Recruiting
- |||| utidelone IV (UTD1) / Beijing Biostar Technologies
New P2 trial, Monotherapy, Metastases: Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jun 3, 2021
P2, N=120, Recruiting, Sponsor: Beijing Biostar Technologies, Ltd
- | utidelone IV (UTD1) / Beijing Biostar Technologies
Trial completion date, Trial primary completion date, Monotherapy, Metastases: Clinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer?NSCLC? (clinicaltrials.gov) - Jun 2, 2021
P2, N=30, Recruiting, Sponsor: Beijing Biostar Technologies, Ltd
Not yet recruiting --> Recruiting Trial completion date: Jun 2021 --> Sep 2021 | Trial primary completion date: Dec 2020 --> Sep 2021